Payment overview · 2025
General Payments
$71.52
4 reported records · 4 companies
Healthcare provider profile · identity verified
Lisa A Kapler, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROCKFORD, IA · NPI 1154337632
Verified facts
What the public records show
CMS Open Payments records show Lisa A Kapler, MD received $71.52 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.54 | 28.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.17 | 25.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.60 | 24.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.21 | 21.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $71.52 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 60 |
| Lisinopril | Lisinopril | 276 | 56 |
| Omeprazole | Omeprazole | 267 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 253 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 43 |
| Warfarin Sodium | Warfarin Sodium | 247 | 25 |
| Furosemide | Furosemide | 227 | 40 |
| Famotidine | Famotidine | 204 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 33 |
| Potassium Chloride | Potassium Chloride | 189 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 186 | 35 |
| Losartan Potassium | Losartan Potassium | 177 | 38 |
| Carvedilol | Carvedilol | 172 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 148 | 19 |
| Gabapentin | Gabapentin | 146 | 32 |
| Sertraline Hcl | Sertraline Hcl | 143 | 24 |
| Allopurinol | Allopurinol | 138 | 19 |
| Trazodone Hcl | Trazodone Hcl | 136 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 21 |
| Mirtazapine | Mirtazapine | 126 | 17 |
| Metformin Hcl | Metformin Hcl | 122 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 42 |
| Spironolactone | Spironolactone | 119 | 23 |
| Cephalexin | Cephalexin | 114 | 60 |
| Eliquis | Apixaban | 108 | 17 |
| Torsemide | Torsemide | 108 | 20 |
| Tramadol Hcl | Tramadol Hcl | 107 | 14 |
| Prednisone | Prednisone | 105 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 17 |
| Bupropion Xl | Bupropion Hcl | 91 | 15 |
| Buspirone Hcl | Buspirone Hcl | 89 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | suppressed |
| Risperidone | Risperidone | 79 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 20 |
| Donepezil Hcl | Donepezil Hcl | 68 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Simvastatin | Simvastatin | 60 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Azithromycin | Azithromycin | 50 | 37 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 21 |
| Alprazolam | Alprazolam | 47 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 43 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 15 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Fluconazole | Fluconazole | 35 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 28 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Atenolol | Atenolol | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 12 |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | 14 |
| Baclofen | Baclofen | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $71.52 · 4 records | ABBVIE INC. | AIRSUPRA, PAXLOVID, VRAYLAR, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error